Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

被引：0
|
作者：
Wang, Y. -Y. [1 ]
Gu, Z. -T. [1 ]
Bao, F. -C. [1 ]
Mao, T. [1 ]
Ji, C. -Y. [1 ]
Fang, W. -T. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Aumolertinib; Neoadjuvant targeted therapy; EGFR-mutated NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP07.05-17
引用
收藏
页码：S565 / S565
页数：1
相关论文
共 50 条
  • [31] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [32] RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer
    Yun, N.
    Naqib, A.
    Borgia, J. A.
    Fidler, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S458 - S459
  • [33] RNA sequencing to characterize pathways in EGFR-mutated non-small cell lung cancer
    Yun, Nicole
    Naqib, Ankur D.
    Borgia, Jeffrey Allen
    Batus, Marta
    Fidler, Mary Jo J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
    Inoue, Akira
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2020, 96 (07): : 266 - 272
  • [35] Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer
    Zhao, Q.
    Deng, L.
    Zhang, Y.
    Zhou, X.
    Li, Y.
    Yu, M.
    Zhou, L.
    Zou, B.
    Liu, Y.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Lara-Mejia, Luis
    Sanchez-Reyes, Roberto
    Aviles-Salas, Alejandro
    Arrieta-Rodriguez, Oscar
    ONCOLOGY-NEW YORK, 2020, 34 (01): : 21 - 27
  • [37] Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I-III non-small cell lung cancer with high-risk pathological factors
    Chen, X.
    He, J.
    Shen, H.
    Xi, Y.
    Chen, B.
    He, X.
    Gao, J.
    Yu, H.
    Shen, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S97 - S97
  • [38] Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
    Lee, Chee Khoon
    Man, Johnathan
    Lord, Sally
    Links, Matthew
    Gebski, Val
    Mok, Tony
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 403 - 407
  • [39] A population-adjusted indirect treatment comparison of efficacy and safety of aumolertinib vs osimertinib in EGFR-mutated non-small cell lung cancer
    King, Sarah
    Stergiopoulos, Stella
    Curtis, Melissa
    Dillon, Andrew
    Akehurst, Ron
    Lee, Dawn
    Guelfucci, Florent
    Ngami, Armel
    Bianic, Florence
    Li, You
    Ma, Xiwen
    Ali, Siraj
    Miller, Vincent
    Popat, Sanjay
    LUNG CANCER, 2023, 178 : S36 - S37
  • [40] The Response of EGFR-Mutated Non-Small Cell Lung Cancer Spine Metastases to Stereotactic Body Radiation Therapy
    Zhuang, R. H.
    Balagamwala, E. H.
    Reddy, C. A.
    Lee, M. Y.
    Angelov, L.
    Chao, S. T.
    Suh, J. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E450 - E450
12345